ATROPINE INJECTION BP SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

ATROPINE SULFATE

제공처:

HIKMA CANADA LIMITED

ATC 코드:

A03BA01

INN (국제 이름):

ATROPINE

복용량:

0.6MG

약제 형태:

SOLUTION

구성:

ATROPINE SULFATE 0.6MG

관리 경로:

INTRAMUSCULAR

패키지 단위:

15G/50G

처방전 유형:

Prescription

치료 영역:

ANTIMUSCARINICS ANTISPASMODICS

제품 요약:

Active ingredient group (AIG) number: 0104748005; AHFS:

승인 상태:

APPROVED

승인 날짜:

2014-10-02

제품 특성 요약

PRESCRIBING INFORMATION
Pr
ATROPINE INJECTION
BP
0.4 mg / mL, and 0.6 mg / mL atropine sulfate solution
For intramuscular, intravenous and subcutaneous use
Anticholinergic
Hikma Canada Limited
5995 Avebury Road, Suite 804
Mississauga, Ontario
L5R 3P9
DATE OF PREPARATION:
April 22, 2022
Control number: 262701
PRESCRIBING INFORMATION
Pr
ATROPINE INJECTION BP
0.4 mg / mL, and 0.6 mg / mL atropine sulfate solution
Anticholinergic
ACTION AND CLINICAL PHARMACOLOGY
Atropine is commonly classified as an anticholinergic or
parasympatholytic drug. More
precisely however, it is termed an antimuscarinic agent since it
antagonizes the muscarinic-like
actions of acetylcholine and other esters.
Atropine inhibits the muscarinic actions of acetylcholine on
structures innervated by
postganglionic cholinergic nerves, and on smooth muscles which respond
to endogenous
acetylcholine but are not so innervated. The major action of atropine
is a competitive
antagonism which can be overcome by increasing the concentration of
acetylcholine at receptor
sites of the effector organ (e.g. by using anticholinesterase agents
which inhibit the enzymatic
destruction of acetylcholine). The receptors antagonized by atropine
are the peripheral structures
that are stimulated or inhibited by muscarine (i.e. exocrine glands
and smooth and cardiac
muscle). Responses to postganglionic cholinergic nerve solution also
may be inhibited by
atropine, but this occurs less readily than with responses to injected
(exogenous) choline esters.
Atropine induced parasympathetic inhibition may be preceded by a
transient phase of
stimulation, especially on the heart where small doses first slow the
rate before characteristic
tachycardia develops due to paralysis of vagal control. In clinical
doses (≈ 1 mg), atropine does
not depress the CNS, but may stimulate the medula and higher cerebral
centres. Although mild
vagal excitation occurs, the increased respiratory rate and
(sometimes) increased depth of
respiration produced by atropine are probably the result of
bronchi